Genomind Launches Open Label Study for PGx-Guided Psychiatric Therapy | GenomeWeb

Originally published May 15.

At the American Psychiatric Association annual meeting last week, personalized medicine-focused firm Genomind outlined plans for using online informed consent forms and surveys to efficiently conduct studies involving its Genecept Assay.

Genomind is planning to conduct open-label studies to gauge whether its test can inform treatment decisions and improve outcomes for patients with depression, anxiety, biopolar disorder, and schizophrenia.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nature this week: genetic link between birth weight and adult-onset diseases, and more.

Even with all the current enthusiasm for gene therapies, Tech Review cautions that they are mostly in the early stages of development.

DNA phenotyping puts a potential face to a suspect in a nearly 25-year-old murder, the AP reports.

Researchers discuss the need for antibody standards at a meeting, NPR reports.